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Abstract 
Background and Aim: Calprotectin is an abundant protein in neutrophils, which 
infiltrate the mucosa during inflammation. Fecal calprotectin (FC) level has shown 
correlation with disease activity in ulcerative colitis (UC) patients. Additionally, FC level 
is expected to indicate mucosal healing (MH). This study was to see the significance of 
FC for predicting MH in patients with quiescent UC. 
Methods: A total of 112 patients with quiescent UC were included. After taking blood 
and stool samples, patients underwent total colonoscopy and the Mayo endoscopic 
subscore was recorded. FC was measured by fluorescence enzyme immunoassay. C-
reactive protein, hemoglobin, erythrocyte sedimentation rate, and serum albumin were 
measured as conventional biomarkers. MH was defined as Mayo 0 or 0&1, and receiver 
operator characteristic (ROC) analyses were undertaken to determine the significance 
levels of measurements. 
Results: Data from 105 patients were available. Eleven patients showed Mayo ≥2. The 
median (interquartile range) of FC level of all patients was 115μg/g (45.4-420). The area 
under the curve (AUC) in ROC analysis of FC to predict Mayo 0&1 was 0.869 with a 
cut-off value of 200μg/g yielding 67% sensitivity and 91% specificity, which were the 
best among all biomarkers. However, the power of FC to predict Mayo 0 was modest; the 
AUC was 0.639, cut-off value 194μg/g with 71% sensitivity and 58% specificity. 
Conclusions: Based on the findings of this study, we believe that FC is a clinically 
relevant biomarker of MH in patients with quiescent UC. Other favorable features of FC 
test include feasibility and non-invasiveness. 
 
Key words: Ulcerative colitis; Fecal calprotectin; Mucosal healing; Biomarker. 
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1. Introduction 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of the large 
intestine with remitting and relapsing course. Although historically, the assessment of 
disease activity has relied on clinical symptoms, the current gold standard is colonoscopy 
because symptoms do not necessarily reflect active inflammation in the mucosa.1 Given 
that colonoscopy is a major undertaking for the physicians and may cause patients 
discomfort, more simple and reliable surrogate markers of intestinal inflammation are 
desirable. Fecal calprotectin (FC) is a calcium-binding, cytosolic protein found in 
abundant amounts within neutrophils. The fecal level of calprotectin increases at the time 
of bowel inflammation when neutrophils infiltrate the mucosal tissue in very large 
numbers.2,3 Accordingly, FC levels are reported to correlate well with endoscopic indices 
of UC activity including the Matts’ index,4 Sutherland criteria,5 Rachmilewitz index,6 and 
the Mayo endoscopic subscore,7 indicating clinically relevant diagnostic value for FC. In 
addition, elevated FC has been related to an increased risk of IBD relapse.8,9 
 
The primary goal in the management of UC is rapid remission of symptoms. However, 
given the relapsing-remitting nature of this immune disorder, it is important to avoid 
colectomy, prevent colorectal cancer and minimize hospitalization time. Accumulating 
data indicate that achievement of mucosal healing (MH) is associated with lower risk of 
such long term outcomes, irrespective of medical therapies.10,11,12,13 Therefore, currently, 
MH is considered as an ideal therapeutic goal in the management of disease activity in 
IBD patients. Further, although MH is expected in patients with clinical remission, but it 
has been reported that a subgroup of patients have persistently active inflammation while 
in clinical remission.14-16 Therefore, except for periodic surveillance, there is no 
compelling evidence supporting the necessity and benefit of monitoring MH by 
endoscopy.15 Obviously, a less invasive surrogate marker to identify patients with MH is 
preferable in clinical settings. 
 
In recent years, various biomarkers of MH have been explored. However, because in UC 
patients, inflammation is mainly confined to the colon and the rectum, it may be 
reasonable that a fecal marker is more accurate than a serum marker like C-reactive 
4 
 
protein (CRP). Indeed, one study found that CRP was a relevant biomarker only in 
patients with extensive UC.17 In recent years, there has been a growing interest to apply 
FC level to predict disease activity in UC patients5,7,18,19 instead of CRP.6  
 
Our major interest in this study was to see if FC level is associated with MH in patients 
with quiescent UC (clinically judged to be in remission). Additionally, we wished to 
compare its predictive value with other conventional biomarkers, including CRP, 
hemoglobin, erythrocyte sedimentation rate (ESR), and albumin. 
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2. Methods 
2. 1. Patients 
In a multicenter setting, 112 patients with a diagnosis of UC were invited to participate in 
this study between October 2013 and November 2014. Patients’ UC had been diagnosed 
according to established clinical, endoscopic, radiological, and histological criteria. The 
criteria for inclusion in this investigation required a patient to have been in clinical 
remission for at least 3 months prior to entry and was about to undergo scheduled 
colonoscopy. In Japan, there has been a nationwide registration system for patients with 
inflammatory bowel diseases. Patients and attending physicians are annually required to 
submit detailed clinical information including colonoscopy findings. Thus, most of 
registered patients have undergone serial colonoscopy. The Mayo subscore was applied 
to evaluate clinical activity, while clinical remission was defined as total subscore <1 with 
no rectal bleeding.12,20 Disease extension was confirmed by chart review and was 
classified according to the Montreal classification from the most maximally affected site 
ever recorded.21 Presence of co-morbidities that could cause anemia and/or inflammatory 
reactions, active infection, incomplete colonoscopy (not reaching the caecum) and 
inability to collect blood or stool samples were exclusion criteria. Also, patients who had 
colorectal cancer, a history of bowel surgery and were regular users of low-dose aspirin 
and/or non-steroidal anti-inflammatory drugs (NSAID, more than 2 tablets per week) 
were excluded because potentially these might influence FC level. 
 
2. 2. Study Protocol 
This was a prospective observational study. Patients collected stool samples within the 
previous 3 days of the index colonoscopy (before cleansing) and the stool samples were 
stored at -20ºC until assay. After bowel preparation with electrolyte or polyethylene 
glycerol cleansing reagent, patients underwent total colonoscopy and endoscopic 
component of the Mayo score was used to assess MH. The greatest score in any 
anatomical site was recorded and MH was defined as Mayo 0 & 1 or Mayo 0. Blood 
samples were taken at the beginning of colonoscopy measuring CRP (normal reference 
range <0.2 mg/dL), hemoglobin (normal reference range for men 14-17 g/dL, women 12-
15 g/dL), ESR, and serum albumin (normal reference range 4.0-5.0 g/dL) by routine 
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laboratory methods. 
 
2. 3. Assay of fecal calprotectin 
The stool samples were sent to Thermo Fisher Scientific in dry ice and calprotectin was 
measured in a blind study manner regarding the clinical and endoscopic profile. Briefly, 
after thawing, the appropriate stool samples were homogenized by mixing with a 
predefined extraction buffer volume. After centrifugation, the supernatants were 
subjected to fluorescence enzyme immunoassay using the EliA Calprotectin 2. The 
measurements were done in duplicates and the average was used for evaluation analyses. 
Currently, no published data regarding normal FC levels in Japanese population is 
available. 
 
2. 4. Ethical Considerations 
Prior to the initiation of the study, our investigation protocol was reviewed and approved 
by the Institutional Review Board at each study center listed on the title page. All included 
patients provided informed consent at enrollment after being informed of the study 
purpose and the nature of the procedures involved. Additionally, throughout the study, 
adherence was made to the Helsinki Declaration. 
 
2. 5. Statistical analysis 
Numerical variables are expressed as median and interquartile range (IQR) values, while 
categorical variables are presented as frequencies. For comparison of numerical and 
categorical variables, the Mann-Whitney U test and the chi-square test or Fischer’s exact 
test were applied as appropriate. A receiver operator characteristic (ROC) graph was 
drawn to estimate the area under the curve (AUC) and the best cut-off levels for each 
biomarker to predict MH. According to the cut-off levels, test significance including 
sensitivity (SENS), specificity (SPEC), positive predictive value (PPV), positive 
likelihood ratio (PLR), and accuracy rate (AR) were calculated. Two sided P values <0.05 
were considered to be statistically significant. Statistical analyses were done by using a 
JMP version 10.0.2 statistical package. 
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3. Results 
3. 1. Patients’ baseline demographic variables 
Among the 112 patients initially included, 3 patients failed to provide stool samples, 1 
had incomplete colonoscopy, and 3 had taken NSAID or low-dose aspirin. Therefore, 105 
of the 112 patients were available for inclusion in the final assessments of the study 
outcomes. The main demographic variables of the included patients are presented in Table 
1. The median age was 45 (IQR 36-54) years, and 58 (55%) were male. Likewise, the 
median age at diagnosis was 36 (IQR 26-52) years and the median duration of UC was 
5.6 (IRQ 1.8-8) years. Twenty-two patients were current smokers (21%). The extent of 
UC was total colitis, 62 (59%); left-sided, 24 (23%) and proctitis, 19 (18%). All, but 3 
patients were at least on one medication as a maintenance therapy; 102 were on oral 
aminosalicylates, 14 were on a immunomodulator, and 11were on biologics. No patient 
was on a corticosteroid. 
 
3. 2. Colonoscopic findings, fecal calprotectin, and laboratory data 
In spite of the included patients being in clinical remission, 11 (10%) showed Mayo score 
≥2; 52 (49%) Mayo score 0; 42 (40%) Mayo score 1; 10 (10%) Mayo score 2 and 1 Mayo 
score 3. The Median (IQR) value for FC level of all patients was 115 (45.4-420) μg/g. FC 
levels stratified according to the Mayo score are presented in Figure 1. The median (IQR) 
FC levels in patients with Mayo 0, 1, and 2 were 91 (33.8-291.5) μg/g, 110.5 (43.3-435.8) 
μg/g, and 728 (238.5-5165.75) μg/g, respectively. The FC level of the only patient with 
Mayo 3 was 3599 μg/g. The median FC levels in patients with Mayo 0 & 1, 2 & 3, and 
1-3 were 96.2 (40.5-354) μg/g, 877 (248-4420) μg/g, and 200 (53.5-730.5) μg/g, 
respectively. As seen in Table 2, there was a significant difference in FC levels between 
patients with Mayo 0 & 1 and 2 & 3 (P<0.001) as well as between Mayo 0 and Mayo 1-
3 (P=0.01). Because our study population was in clinical remission, the results of blood 
markers were close to normal values (data not shown). The median (IQR) for CRP in 
patients with Mayo 0 & 1 and 2 & 3 were 0.04 mg/dL (0.04-0.07 mg/dL) and 0.12 mg/dL 
(0.04-0.36 mg/dL), respectively (P=0.007). Likewise, we found a significant difference 
in the median CRP values between patients with Mayo 0 and 1-3 (P=0.03). 
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3. 3. Results of ROC analyses 
We firstly analyzed the data by defining the Mayo 0 & 1 as MH. Figure 2 shows the ROC 
graphs for FC values. The AUC with 95% confidence interval (CI) of all biomarkers are 
shown in Table 3. The AUC for FC level was 0.869 (95% CI: 0.734-0.941) with 
significant differences between FC and hemoglobin (P=0.001), ESR (P=0.0005), and 
albumin (P=0.0004). The AUC of CRP was 0.743 (95% CI: 0.566-0.866) with no 
significant difference between CRP and FC (P=0.18). The estimated cut-off values and 
the test features of all markers are shown in Table 4. The cut-off level for FC to predict 
MH was 200 μg/g with 67% sensitivity, 91% specificity, 98% PPV, 7.37 PLR, and 70% 
AR. The corresponding values for CRP were 68%, 70%, 95%, 2.27, and 68%, 
respectively based on the cut-off level of 0.04 mg/dL CRP. Finally, we sought to see the 
performance of FC level to predict Mayo score 0. Figure 3 shows the ROC graphs of FC 
values. The AUC for FC level was 0.639 (95% CI: 0.528-0.737) and significant 
differences were no longer seen between FC level and any other biomarker we monitored 
(Table 3). In addition, test characteristics of FC levels were not as good as those of Mayo 
score 0 & 1 (Table 4). Based on the cut-off value of 194 μg/g, the sensitivity, specificity, 
PPV, PLR, and AR values were 71%, 53%, 60%, 1.51, and 62%, respectively. 
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4. Discussion 
Our major objective in this study was to see the potential of FC as a biomarker for 
assessing MH in clinical settings. In other words, could FC assay spare some patients 
from colonoscopy, what was the diagnostic power of FC when the status of MH is to be 
known. The FC level showed good test reliability for predicting MH among UC patients 
who were judged to be in clinical remission when MH could be defined as Mayo score 
≤1. Judging by AUC values and the test characteristics, FC appeared to offer better 
sensitivity and specificity than any other biomarkers we monitored in this study. 
Therefore, at present, FC might be the most reliable biomarker for predicting MH in 
clinical settings, except that the test performance of FC to predict Mayo 0 appeared to be 
weak. However, at the start, we defined MH as Mayo ≤1 because this is the most widely 
applied in clinical trials and therefore, should be the best indicator to judge the predictive 
value of FC. Further, our results are consistent with earlier reports on the application of 
FC to assess disease activity in IBD patients.5-7,18,19 
 
Evolving evidence indicates that MH is a major factor if one is to achieve favorable long-
term clinical course, particularly when future colectomy is a concern. This is why 
monitoring MH is currently of great interest to gastroenterologists. In patients with active 
UC, discordance of clinical symptoms and endoscopic findings is not rare. This has led 
to colonoscopy being considered as a gold standard to assess MH. Indeed, there is a 
subgroup of symptomatic patients with MH, but this may reflect classical UC to have 
been complicated by irritable bowel syndrome (IBS).22 In such cases, colonoscopy could 
be a reasonable option to exclude IBS. On this note, one should bear in mind that most 
physicians are reluctant to undertake colonoscopy when patients are asymptomatic 
because colonoscopy causes patient discomfort as well as carrying the likelihood of 
colonoscopy reactivation an otherwise quiescent UC.23 Based on these understandings, 
we thought that FC could be an ideal approach to assess MH when UC patients are in 
clinical remission. 
 
In this study, we found that about 10% of UC patients had residual inflammation in the 
mucosa (Mayo ≥2) in spite of having been judged to be in clinical remission. In fact, 
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complete MH (Mayo 0) was seen in only half of the patients. This 10% fraction is with 
underlying inflammation in line with previous reports involving cohorts of asymptomatic 
patients with Mayo ≥2 that accounted for 13%16 and 31%,18 while the fraction with Mayo 
score 0 in patients with quiescent UC was found to be 47% to 60%.15,16,19 Further, it 
should be appropriate to mention that the only patient in our study with Mayo 3 was on 
biologics at the time of colonoscopy and the residual inflammation was confined to the 
ascending colon, which could be the reason for absence of obvious signs of active disease. 
These observations suggest that even during clinical remission, signs of disease activity 
should justify interventions to suppress a likely relapse. Additionally, a substantial 
fraction of patients (33%) with Mayo score 0 or 1 showed elevated FC despite significant 
differences in the median FC levels between Mayo 0 & 1 and 2 & 3 and between Mayo 
0 and Mayo 1-3. FC is derived from neutrophils, which infiltrate the colonic mucosa 
during active IBD.24,25 When a patient achieves remission, inflammation is alleviated and 
mucosal healing is in progress, the infiltrated neutrophils do not return to the circulation, 
but are gradually shed into the gut, which will continue over time after patients have been 
judged to be in clinical remission. In line with these assertions, Hanai, et al.4 found that 
while UC clinical activity index (CAI) had reached the remission level (CAI ≤ 4), FC 
continued to be high. This could be a credible explanation for elevated FC in patients 
judged to be in clinical remission. 
 
Based on the interpretations of the ROC graphs, we obtained a cut-off FC level of 200 
μg/g to predict MH. However, hitherto, there has been no agreement regarding an 
appropriate cut-off level for FC to predict MH.5,6,7,18,19 This is not surprising because there 
are potential confounding factors influencing measurement as well as the interpretation 
of FC levels including what endoscopic criteria is used to define MH and methodological 
approaches to assay FC. Labaera, et al.26 reported results of an informative study 
comparing test performance of currently available FC assays and applying the Mayo score 
as definition of MH. Test characteristics including sensitivity, specificity, and positive 
predictive values were reasonably comparable, but the cut-off levels of the measurements 
were inconsistent, indicating that a validated reproducible FC assay is essential for 
assessing MH based on FC.  
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In this study, all patients underwent total colonoscopy, but the original endoscopic items 
of the Mayo scoring system was evaluated by sigmoidscopy.20 Diffusely inflamed mucosa 
from the rectum towards the proximal colon was a hallmark of UC. However, patchy 
distribution of the inflamed mucosa either at the time of diagnosis or during the course of 
disease have also been reported.27,28 Indeed, among the 11 patients who showed Mayo 
score ≥2, the most frequent residual inflammation was observed was 2 in the ascending 
colon and 2 in the descending colon, reflecting the importance of total colonoscopy when 
assessing MH. The median FC in the Mayo score 2 & 3 was 877 μg/g and none but one 
patient with Mayo score ≥2 had FC level below the cut-off level, suggesting FC may be 
a powerful biomarker particularly in patients undergoing incomplete intubation. Further, 
among the other biomarkers (CRP, ESR, Hb, Albumin), we found statistically significant 
differences only in the median CRP level between Mayo 0 & 1 and 2 & 3 and between 
Mayo 0 and 1-3. Also, there was no significant difference in the AUC to predict Mayo 0 
& 1 between FC and CRP and sensitivity and specificity of CRP were 68% and 70%, 
respectively. CRP, therefore, could be a relevant biomarker to predict MH in some 
patients, but its positive likelihood ratio was 2.27. Our results are in agreement with the 
Rosenberg’s report showing that CRP alone had modest ability to predict MH in patients 
with UC in remission.16 Furthermore, according to our experience CRP levels are masked 
by corticosteroid. Therefore, CRP may not be an appropriate biomarker for predicting 
MH. 
 
At this point, we like to acknowledge limitations of our study, how and if these could 
have compromised our conclusions. First, we included patients with quiescent UC, which 
means our FC data is valid only in this clinical setting, and we might have under estimated 
the FC level. However, as discussed above, our intention was to assess the validity of FC 
for judging MH, and to see if FC assay can spare some patients from colonoscopy. Second, 
the central reading of video to minimize inter-observer variation in colonoscopy was not 
done. With this in mind, in all patients, only well experienced endoscopists carried out 
the colonoscopy work. Similarly, Osada, et al.29 reported that Mayo score had a good 
concordance regarding intra- and inter-observer recordings when the endoscopists were 
those who routinely carry out colonoscopy. Third, how close to stool sampling biologics 
was given could influenced the FC levels. However, we confirmed that all patients on 
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biologics sampled stools at least 1week apart from the administrations. Finally, lactoferrin 
is another biomarker of mucosal inflammation,30 but was not measured in this study. 
 
In conclusion, our major objective in this study was to assess the validity of FC as a 
biomarker to judge MH so that potentially, FC could spare patients from colonoscopy if 
such undertaking was to assess MH. Among the biomarkers we measured to assess UC 
activity in the mucosa during apparent quiescent disease, FC appeared to be the most 
reliable biomarker. FC assay showed good test performance, feasible, uncomplicated and 
non-invasive. However, its performance to predict MH related to Mayo score 0 appeared 
to be modest suggesting that the role FC in clinical setting may be complementary.  
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Figure Legends 
Figure 1. Fecal calprotectin (FC) levels stratified according to the Mayo score are 
presented. The median and interquartile range (IQR) FC levels in patients with Mayo 0, 
1, and 2 were 91 (33.8-291.5) μg/g, 110.5 (43.3-435.8) μg/g, and 728 (238.5-5165.75) 
μg/g, respectively, while the median FC levels in patients with Mayo 0 & 1, 2 & 3, and 
1-3 were 96.2 (40.5-354) μg/g, 877 (248-4420) μg/g, and 200 (53.5-730.5) μg/g, 
respectively. 
 
Figure 2. Receiver operator characteristic (ROC) graphs for fecal calprotectin (FC) levels. 
The area under the curve (AUC) with a 95% confidence interval (CI) for all biomarkers 
are shown in Table 3. The AUC for FC level was 0.869 (95% CI: 0.734-0.941) with 
significant differences between FC and hemoglobin (P=0.001), erythrocyte sedimentation 
rate (P=0.0005), and albumin (P=0.0004). The AUC of C-reactive protein was 0.743 
(95% CI: 0.566-0.866) with no significant difference between CRP and FC (P=0.18).  
 
Figure 3. Receiver operator characteristic (ROC) graphs of fecal calprotectin (FC) to see 
the diagnostic power of FC for predicting Mayo score 0. 
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Table 1.  Baseline demographic variables of the 105 patients included in this study. 
Variable n 
Age (year), median, interquartile (IQR) 45 (36-54) 
Male/Female 58/47 
Age (year) at diagnosis, median, IQR 36 (26-52) 
Disease duration (year), median, IQR 5.6 (1.8-8) 
Disease location (Montreal classification)  
  E1 19 (18%) 
  E2 24 (23%) 
  E3 62 (59%) 
Active smoker 22 (21%) 
Family history 8 (7%) 
Extra-intestinal manifestations 12 (11%) 
Medications  
  5-aminosalicylates (5ASA) 82 (78%) 
  Corticosteroid 0 (0%) 
  5ASA+azathioprine/6-mercaptopurine 9 (9%) 
  5ASA+biologics 6 (6%) 
  5ASA+azathioprine/6-mercaptopurine +biologics 5 (5%) 
  No 3 (2%) 
Mayo score (endoscopic item)  
  0 52 (49%) 
  1 42 (40%) 
  2 10 (10%) 
  3 1 (1%) 
Fecal calprotectin (g/g), median, IQR 115 (45.4-420) 
C-reactive protein (mg/dL), median, IQR 0.04 (0.04 -0.08) 
Hemoglobin (g/dL), median, IQR 13.8 (12.9-15) 
Erythrocyte sedimentation rate (mm/hr), median, IQR 4 (2-8) 
Albumin (g/dL), median, IQR 4.5 (4.3-4.7) 
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Table 2. Median Fecal calprotectin levels (interquartile range) in patients stratified according to the 
Mayo score (μg/g). 
Mayo 0 1 2 3 0 & 1 2 & 3 1-3 
91 
(33.75-291.5) 
110.5 
(43.25-435.75) 
728 
(238.5-5165.75) 
3599 96.2 
(40.5-354) 
877 
(248-4420)* 
200 (53.5-
730.5)** 
*P<0.001 between Mayo 0 & 1 and Mayo 2 & 3; **P=0.001 between Mayo 0 and Mayo 1-3 
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Table 3. Receiver operator characteristic (ROC) plots and the application of area under 
the curve (AUC) to predict and compare Mayo 0 & 1 and Mayo 0. 
Variable AUC 95% CI P value* 
Mayo 0&1 vs Mayo 2&3 
Fecal calprotectin 0.869 0.734-0.941  
C-reactive protein 0.743 0.566-0.866 0.18 
Hemoglobin 0.535 0.327-0.732 0.001 
ESR 0.602 0.439-0.746 0.0005 
Albumin 0.551 0.388-0.704 0.0004 
Mayo 0 vs Mayo 1-3 
Fecal calprotectin 0.639 0.528-0.737  
C-reactive protein 0.616 0.510-0.712 0.75 
Haemoglobin 0.491 0.379-0.604 0.07 
ESR 0.526 0.413-0.637 0.14 
Albumin 0.502 0.391-0.614 0.08 
CI, confidence interval; ESR, erythrocyte sedimentation rate; *Compared with Fecal 
calprotectin. 
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Table 4. Test characteristics (95% confidence interval) of biomarkers to predict Mayo 0 & 1 and 
Mayo 0. 
Variable Cut-off value SENS (%) SPEC (%) PPV (%) PLR AR (%) 
Mayo 0&1 vs Mayo 2&3 
FC 200 μg/g 67 (63-68) 91 (64-98) 98 (94-99) 7.37 (1.78-41.6) 70 (64-71) 
CRP 0.04 mg/dL 68 (65-70) 70 (41-89) 95 (91-98) 2. 27 (1.1-6.35) 68 (63-72) 
Hemoglobin 13.9 g/dL 55 (52-58) 70 (41-89) 94 (89-98) 1.8 5 (0.89-5.22) 57 (51-61) 
ESR 3 mm/hr 49 (46-52) 70 (41-89) 94 (88-98) 1.65 (0.78-4.68) 52 (46-55) 
Albumin 4.3 g/dL 34 (33-37) 90 (62-98) 98 (89-96) 3.59 (0.85-20.4) 41 (36-43) 
Mayo 0 vs Mayo 1-3 
FC 194 g/g 71(62-80) 53(44-61) 60(52-67) 1.51(1.09-2.05) 62 (53-70) 
CRP 0.08 mg/dL 88(80-94) 29(22-35) 55(50-59) 1.25(1.02-1.45) 58 (51-64) 
Haemoglobin 14.4 g/dL 43(34-52) 63(53-72) 54(42-65) 1.16(0.72-1.86) 53 (44-62) 
ESR 2 mm/h 40(31-49) 67(58-76) 56(43-68) 1.23(0.73-2.08) 54 (44-63) 
Albumin 4.7 g/dL 35(27-43) 77(68-85) 60(45-74) 1.5(0.82-2.8) 56 (47-64) 
SENS, sensitivity; SPEC, specificity; PPV, positive predictive value; PLR, positive likelihood ratio; 
AR, accuracy rate; FC, Fecal calprotectin; CRP, C-reactive protein; ESR, erythrocyte sedimentation 
rate. 
 
 
 
 
 
 
